Alterity Locks In A$4.2M Underwriting for ATHO Options to Fund Phase 3 MSA Trial
ATHE sits 71% above its 52-week low of $2.66 on light trading volume (0.3× avg).
Summary
Alterity Therapeutics entered an underwriting agreement with MST Financial Services to underwrite up to 8.4 million ATHO options, raising a minimum of A$4.2 million to fund its Phase 3 MSA trial.
Key Events · Financing and Capital Events · ATHE
-
Underwriting Agreement Executed
MST Financial Services will underwrite up to 8,400,000 ATHO listed options, guaranteeing a minimum raise of approximately A$4.2 million before costs.
-
Funding for Phase 3 MSA Trial
Proceeds will support continued late-stage clinical development of ATH434 in Multiple System Atrophy and general working capital.
-
Option Exercise Terms
Options are exercisable at A$0.50 each and expire at 5:00pm AEST on 31 August 2026. Total options on issue: 15,918,235.
-
Maximum Raise Potential
If all options are exercised, the company could raise up to approximately A$7.96 million before costs.
Analysis · ATHE · Life Sciences
A minimum A$4.2 million (up to A$7.96 million) is now secured through an underwriting agreement for Alterity's expiring ATHO listed options. The capital directly supports the planned Phase 3 pivotal trial for ATH434 in Multiple System Atrophy, a key value driver. Removing uncertainty around option exercise shortfalls, the underwriting strengthens the balance sheet ahead of a critical clinical milestone. The 7% underwriting fee is standard for such arrangements.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82M. The 52-week trading range was $2.66 to $5.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.